Literature DB >> 25016064

Targeted biopharmaceuticals for cancer treatment.

Lufang Zhou1, Ningning Xu2, Yan Sun3, Xiaoguang Margaret Liu4.   

Abstract

Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Protein-based biopharmaceuticals have significantly extended the lives of millions of cancer patients. This article reviews the biological function and application of targeted anticancer biopharmaceuticals. We first discuss the specific antigens and core pathways that are used in the development of targeted cancer therapy. The innovative monoclonal antibodies, non-antibody proteins, and small molecules targeting these antigens or pathways are then reviewed. Finally, the current challenges in anticancer biopharmaceuticals development and the potential solutions to address these challenges are discussed.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer biopharmaceuticals; Biosimilar; Innovative biologics; Targeted therapy

Mesh:

Substances:

Year:  2014        PMID: 25016064     DOI: 10.1016/j.canlet.2014.06.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

Review 1.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

2.  Tumour cell population growth inhibition and cell death induction of functionalized 6-aminoquinolone derivatives.

Authors:  G Franci; G Manfroni; R Cannalire; T Felicetti; O Tabarrini; A Salvato; M L Barreca; L Altucci; V Cecchetti
Journal:  Cell Prolif       Date:  2015-12       Impact factor: 6.831

3.  Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer.

Authors:  Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Jessica L Reedy; Deborah E Citrin; Sunita Chopra; Mansoor M Ahmed; C Norman Coleman
Journal:  Mol Cancer Res       Date:  2018-07-24       Impact factor: 5.852

Review 4.  Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.

Authors:  Mei Liu; Zhiyang Li; Jingjing Yang; Yanyun Jiang; Zhongsi Chen; Zeeshan Ali; Nongyue He; Zhifei Wang
Journal:  Cell Prolif       Date:  2016-06-16       Impact factor: 6.831

Review 5.  Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment.

Authors:  Chengchao Chu; Min Su; Jing Zhu; Dongsheng Li; Hongwei Cheng; Xiaoyuan Chen; Gang Liu
Journal:  Theranostics       Date:  2019-05-18       Impact factor: 11.556

6.  Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy.

Authors:  Yingnan Si; Seulhee Kim; Jianfa Ou; Yun Lu; Patrick Ernst; Kai Chen; Jason Whitt; Angela M Carter; James M Markert; James A Bibb; Herbert Chen; Lufang Zhou; Renata Jaskula-Sztul; Xiaoguang Margaret Liu
Journal:  Cancer Gene Ther       Date:  2020-07-20       Impact factor: 5.987

7.  Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers.

Authors:  Yingnan Si; Ya Zhang; Jia-Shiung Guan; Hanh Giai Ngo; Angela Totoro; Ajeet Pal Singh; Kai Chen; Yuanxin Xu; Eddy S Yang; Lufang Zhou; Runhua Liu; Xiaoguang Margaret Liu
Journal:  Vaccines (Basel)       Date:  2021-08-10

8.  Antibody-Drug Conjugate to Treat Meningiomas.

Authors:  Kai Chen; Yingnan Si; Jianfa Ou; Jia-Shiung Guan; Seulhee Kim; Patrick Ernst; Ya Zhang; Lufang Zhou; Xiaosi Han; Xiaoguang Margaret Liu
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-02

9.  The caspase 3-dependent apoptotic effect of pycnogenol in human oral squamous cell carcinoma HSC-3 cells.

Authors:  In-Hyoung Yang; Ji-Ae Shin; Lee-Han Kim; Ki Han Kwon; Sung-Dae Cho
Journal:  J Clin Biochem Nutr       Date:  2015-12-08       Impact factor: 3.114

10.  3D matrix-based cell cultures: Automated analysis of tumor cell survival and proliferation.

Authors:  Iris Eke; Stephanie Hehlgans; Veit Sandfort; Nils Cordes
Journal:  Int J Oncol       Date:  2015-11-04       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.